Rectal Cancer Research
Clinical research at Rabin Medical Center includes locally advanced rectal cancer, with attention to stage II and stage III disease defined by T3-4N0M0 and TxN1-2M0 patterns.
- Locally advanced rectal cancer
- Stage II and stage III disease
- Preoperative treatment strategies
The sponsor’s research interest in this area centers on treatment approaches intended to improve surgical outcomes in rectal malignancy.
Total Neoadjuvant Therapy
The trial portfolio includes total neoadjuvant treatment for rectal cancer, reflecting an interest in combined systemic and local treatment pathways before definitive surgery.
- Total neoadjuvant treatment
- Multimodal rectal cancer management
- TME-free survival
Research activity in this domain focuses on preserving the need for total mesorectal excision while maintaining disease control.
Immunotherapy in Solid Tumors
Rabin Medical Center is involved in studies evaluating tislelizumab within rectal cancer treatment, indicating therapeutic interest in immune checkpoint blockade for solid tumors.
- Tislelizumab
- Immune-based treatment
- Checkpoint inhibitor therapy
This area links immunologic treatment strategies with standard oncologic care in gastrointestinal malignancy.
Colorectal Oncology
The sponsor’s clinical research landscape is concentrated in colorectal cancer, especially disease located in the rectum, where organ-preserving and surgery-sparing approaches are being explored.
- Colorectal cancer
- Rectal tumor management
- Organ preservation strategies
These interests place emphasis on treatment selection for patients with locally confined but advanced rectal disease.
